News

OrthoPediatrics Corps Reveals Third Quarter Insights and Updates

OrthoPediatrics Corps Reveals Third Quarter Insights and Updates

OrthoPediatrics Third Quarter Update

OrthoPediatrics Corp. (NASDAQ: KIDS), a leader in the pediatric orthopedic field, has shared its preliminary unaudited financial results for the third quarter of 2025, outlining the company’s successes and adjustments for the upcoming year. The company, dedicated to enhancing the lives of children with orthopedic conditions, showcased a strong performance in helping young patients while forecasting strategic changes in its guidance.

Highlights from the Third Quarter

In the third quarter of 2025, OrthoPediatrics made a significant impact, assisting over 37,100 children and bringing the total served since its inception to approximately 1.3 million. The preliminary revenue figures reflect a robust operational performance: the company reported an estimated net revenue of about $61.2 million, marking a growth of 12% from the same period in 2024. Domestic revenue accounted for approximately $48.7 million, showcasing an impressive 14% year-over-year increase, while international revenue was expected to reach around $12.5 million, a 6% growth in the same timeframe.

Detailed Revenue Growth Analysis

When excluding 7D capital sales, the preliminary net revenue for the third quarter amounted to $60.7 million, indicating a notable 17% increase compared to $51.8 million from the third quarter of the previous year. The domestic market, excluding these capital sales, contributed approximately $48.2 million and demonstrated a 19% growth over the prior year’s numbers. OrthoPediatrics' leadership acknowledged the variability related to the timing of capital sales and emphasized their transparent approach in updating their financial expectations for the rest of 2025.

Updated Financial Guidance for 2025

Looking ahead, OrthoPediatrics has revised its 2025 revenue guidance to a range of $233.5 million to $234.5 million, a reduction from the earlier prediction of $237.0 million to $242.0 million. They project growth of 14% to 15% compared to revenue from 2024. The company is also maintaining an anticipated annual set deployment at $15.0 million, as well as adjusted EBITDA guidance between $15.0 million to $17.0 million for the same year.

Operational Challenges and Commitment

David Bailey, President & CEO of OrthoPediatrics, addressed the challenges faced in the latter part of September, particularly the delays in 7D capital sales and fluctuations in the Latin and South American markets. These factors were acknowledged as the primary reasons for the revenue shortfall against the company’s expectations. Despite these hurdles, Bailey reaffirmed the commitment of OrthoPediatrics to driving profitable growth, which aims to reach cash flow break-even by 2026. He emphasized that their extensive product portfolio, comprising OPSB braces and services, positions them uniquely in the pediatric orthopedic market.

Future Engagements and Financial Transparency

The preliminary net revenue estimates disclosed by OrthoPediatrics are subject to adjustments pending the completion of reviews by their independent auditors. To ensure maximum transparency, the company plans to hold a conference call to discuss these results, providing interested investors the opportunity to gain additional insights into their financial performance.

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is exclusively committed to the pediatric orthopedic sector, having developed an extensive range of products aimed at improving the quality of life for children with orthopedic challenges. With over 80 products available, OrthoPediatrics specializes in areas such as trauma, deformity correction, scoliosis, and sports medicine. Their global sales capabilities extend to over 70 countries, ensuring that their impact is felt worldwide.

Frequently Asked Questions

What were OrthoPediatrics' revenue results for Q3 2025?

The preliminary net revenue for Q3 2025 was approximately $61.2 million, marking a 12% increase compared to the same quarter in 2024.

What is the updated revenue guidance for OrthoPediatrics in 2025?

The revised revenue guidance for 2025 is set between $233.5 million and $234.5 million, which is lower than previous forecasts.

How many children has OrthoPediatrics served?

OrthoPediatrics has helped over 1.3 million children since its inception.

What challenges did the company face recently?

The company faced challenges such as delays in 7D capital sales and fluctuations in the Latin and South American markets, affecting revenue expectations.

What is the significance of the OPSB braces?

The OPSB braces are an essential part of OrthoPediatrics' comprehensive product offering, designed to support children's orthopedic needs.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 94

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 111

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 105

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Surgery Partners Deal Faces Fresh Price Scrutiny Ahead

Updated Category News Views 66

A $23.50 cash offer can look wonderfully tidy until somebody asks how the number was built. That is where Surgery Partners shareholders find themselves after Halper Sadeh LLC said it is investigating the proposed sale of Surgery Partners, Inc. to HealthSpan Partners. The firm is examining whether the company’s board obtained a fair price, ran a conflict-free process,...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 23

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
Bybit Adds ANT, but Trading Access Has Real Fine Print

Updated Category News Views 50

Anthropic shares have landed on Bybit Stocks, and the headline is simple enough: eligible customers can trade ANT after the company’s public listing. But this is one of those announcements where the plumbing deserves as much attention as the shiny new ticker. A platform can make access feel effortless right up until a jurisdiction rule, a verification hurdle, or a...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 65

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 47

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading

Top 5 Most Recently Viewed Articles

Deere & Co's Future Amid Repair Debates and Financial Insights

Updated Category News Views 81

Barclays Reconfirms Target for Deere & Co Barclays recently reaffirmed its Overweight rating on Deere & Co (NYSE: DE) and maintained a $400 price target, amidst an ongoing dialogue surrounding the right to repair. This discussion has re-emerged in the spotlight, temporarily impacting Deere's share price before it regained ground. The analyst noted that this issue has been...

Continue Reading
Inventor Offers Hospital Sign to Prevent Infections

Updated Category News Views 38

A Fresh Take on Infection Control Some days you stumble across an idea that just clicks—like the latest gadget for hospitals. Forget complex systems or high-tech cameras; this is about a simple sign that screams 'stop!' before you walk into trouble. It’s designed to safeguard hospital staff by alerting them to take precautions before entering rooms with infectious...

Continue Reading
JPMorgan Adjusts NOV Stock Outlook Amidst Market Challenges

Updated Category News Views 64

JPMorgan Adjusts NOV Stock Outlook Recently, JPMorgan made changes to its financial outlook for NOV Inc. (NYSE: NOV), a key player in the energy equipment and services sector. The investment firm lowered its price target from $23 to $22 but maintained an Overweight rating on the stock. This adjustment was driven by expectations of a slowdown in North American operations...

Continue Reading
Madrigal Pharmaceuticals Expands Workforce with Incentive Awards

Updated Category News Views 234

Madrigal Pharmaceuticals Strengthens Workforce with New Grants Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a leading biopharmaceutical company dedicated to innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), has recently taken a significant step to bolster its team. The company announced granting equity inducement awards to 76 new...

Continue Reading
Pomerantz Investigates Investor Claims Against Abacus Global Management

Updated Category News Views 272

Pomerantz Law Firm's Investigation into Abacus Global Management In recent news, the Pomerantz Law Firm has embarked on an investigation regarding Abacus Global Management, Inc. (NASDAQ: ABL). This investigation revolves around potential securities fraud and other unlawful business practices committed by the company and some of its executive members. For investors...

Continue Reading